New Endoscopic Device Offers Minimally Invasive Approach to Obesity Management

Obesity is increasing worldwide, and many patients face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options for weight management. A newly launched device now offers gastric mucosal ablation for endoscopic obesity therapy and will be the focus of hands-on training and a dedicated symposium.

Erbe Elektromedizin GmbH has introduced MOVIVA, a hybrid instrument designed for gastric mucosal ablation in endoscopic obesity therapy. The system will be a central feature of the company’s activities at ESGE Days 2026 in Milan, where clinicians can evaluate the technology during dedicated hands-on sessions and an on-site symposium. The launch coincides with the company’s 175th anniversary year.

MOVIVA is engineered to target hunger signaling at its source in the gastric fundus, a primary site of ghrelin production. The device combines two functions in a single instrument: injection of a submucosal fluid cushion to protect deeper tissue layers from thermal injury, followed by superficial mucosal ablation using argon plasma coagulation. The platform is powered by the moveAPD mode to support broad and consistent ablation.

The device is currently available in CE and CE-related markets. This availability aligns with the product’s presentation at ESGE Days, where attendees can access hands-on training and educational programming. A dedicated session will review early clinical experience and discuss the role of this endoscopic therapy.

Early clinical evidence indicates that fundal gastric mucosal ablation with MOVIVA induces weight loss. In initial studies, gastric mucosal ablation alone achieved 7.7% total body weight loss at six months. When combined with endoscopic sleeve gastroplasty (ESG), early data show further improvements, with up to 24% total body weight loss at 12 months; more than 150 patients have been treated with MOVIVA to date.

“Obesity continues to rise worldwide, and many patients still face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options. With MOVIVA®, we aim to support physicians in bringing this innovative treatment option into clinical practice and expanding access to minimally invasive obesity therapies,” said Marcus Felstead, Chief Commercial Officer of Erbe.